XML 41 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Disaggregation of Revenue [Line Items]        
Total revenues $ 25,453 $ 14,967 $ 43,485 $ 29,637
Americas        
Disaggregation of Revenue [Line Items]        
Total revenues 5,844 6,906 10,773 12,131
EMEA        
Disaggregation of Revenue [Line Items]        
Total revenues 6,169 3,314 12,450 9,285
APAC        
Disaggregation of Revenue [Line Items]        
Total revenues 13,440 4,747 20,262 8,221
Product revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 14,717 4,504 24,943 9,604
Research and development revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 10,736 10,463 18,542 20,033
Performance Enzymes        
Disaggregation of Revenue [Line Items]        
Total revenues 21,585 7,506 35,815 18,379
Performance Enzymes | Americas        
Disaggregation of Revenue [Line Items]        
Total revenues 3,703 1,173 6,574 4,171
Performance Enzymes | EMEA        
Disaggregation of Revenue [Line Items]        
Total revenues 4,442 1,586 8,979 5,987
Performance Enzymes | APAC        
Disaggregation of Revenue [Line Items]        
Total revenues 13,440 4,747 20,262 8,221
Performance Enzymes | Product revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 14,717 4,504 24,943 9,604
Performance Enzymes | Research and development revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 6,868 3,002 10,872 8,775
Novel Biotherapeutics        
Disaggregation of Revenue [Line Items]        
Total revenues 3,868 7,461 7,670 11,258
Novel Biotherapeutics | Americas        
Disaggregation of Revenue [Line Items]        
Total revenues 2,141 5,733 4,199 7,960
Novel Biotherapeutics | EMEA        
Disaggregation of Revenue [Line Items]        
Total revenues 1,727 1,728 3,471 3,298
Novel Biotherapeutics | APAC        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Novel Biotherapeutics | Product revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Novel Biotherapeutics | Research and development revenue        
Disaggregation of Revenue [Line Items]        
Total revenues $ 3,868 $ 7,461 $ 7,670 $ 11,258